10-K: PAVmed Navigates Financial Headwinds, Strategic Shifts

PAVmed Inc. reports significant financial restructuring, including a reverse stock split and capital raises, while advancing its medical device and diagnostics portfolio amidst ongoing operating losses.

Summary

• PAVmed is a diversified commercial-stage life sciences company operating through independently financed subsidiaries, including Lucid Diagnostics (cancer prevention diagnostics) and Veris Health (digital cancer care).
• The company reported a net loss attributable to PAVmed Inc. common stockholders of $3.774 million for the year ended December 31, 2025, compared to a net income of $31.966 million in 2024 (which included a $72.3 million gain on deconsolidation of Lucid Diagnostics).
• Revenue significantly decreased to $0.071 million in 2025 from $2.995 million in 2024, primarily due to the deconsolidation of Lucid Diagnostics in September 2024.
• Operating loss for 2025 was $21.806 million, compared to $44.487 million in 2024.
• Cash used in operating activities amounted to $5.206 million in 2025, with cash on hand of $1.538 million as of December 31, 2025.
• A 1-for-30 reverse stock split became effective on January 2, 2026, along with a reduction in authorized common stock to 25 million shares, to regain Nasdaq compliance.
• In February 2026, PAVmed raised $30 million through the issuance of Series D Convertible Preferred Stock and warrants, yielding approximately $7.6 million in net proceeds after redeeming Series C Preferred Stock and refinancing the 2022 Note.
• Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for EsoGuard in January 2026, expanding access to esophageal precancer testing.
• Veris Health launched the commercial phase of its strategic partnership with The Ohio State University Comprehensive Cancer Center in October 2025.
• PAVmed licensed exclusive worldwide rights to endoscopic imaging technology from Duke University in February 2026 and appointed Joseph Virgilio as Chief Business Officer for Medical Devices in March 2026.
• The independent registered public accounting firm's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging financial report, marked by recurring losses and going concern doubt, despite strategic advancements in product development, regulatory progress, and new partnerships. The substantial revenue decline due to deconsolidation highlights the need for new revenue streams.

Positives

• Successfully regained compliance with Nasdaq's $1 minimum bid price requirement on January 21, 2026, following a 1-for-30 reverse stock split.
• Lucid Diagnostics was awarded a contract by the U.S. Department of Veterans Affairs for EsoGuard in January 2026, expanding access to esophageal precancer testing across a major integrated healthcare system.
• Veris Health launched the commercial phase of its strategic partnership with The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute in October 2025.
• Lucid Diagnostics was added to the Russell 2000 Index and the Russell 3000 Index on June 27, 2025.
• Highmark Blue Cross Blue Shield issued a positive coverage policy for non-invasive screening of esophageal precancer and cancer in New York state, effective May 26, 2025.
• Lucid submitted a comprehensive clinical evidence package to MolDx in November 2024 to support Medicare coverage reconsideration for EsoGuard, including six new peer-reviewed publications.
• PAVmed licensed exclusive worldwide rights to a multi-modality endoscopic imaging technology from Duke University in February 2026, enhancing its medical device portfolio.
• Joseph Virgilio, an industry veteran, was hired as PAVmed's Chief Business Officer for Medical Devices in March 2026 to oversee portfolio development and commercialization.
• Lucid announced positive 18-month real-world experience data in December 2025 for EsoGuard and EsoCheck, evaluating approximately 12,000 patients and demonstrating high technical success rates and rapid procedure times.
• A case series published in Gastroenterology & Hepatology in September 2025 highlighted EsoGuard's clinical utility in the timely detection of high-grade dysplasia or intramucosal carcinoma in real-world cases.

Negatives

• Incurred a net loss attributable to PAVmed Inc. common stockholders of $3.774 million for the year ended December 31, 2025.
• The company's independent registered public accounting firm's report includes an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.
• Revenue significantly decreased to $0.071 million in 2025 from $2.995 million in 2024, primarily due to the deconsolidation of Lucid Diagnostics.
• Reported an operating loss of $21.806 million in 2025.
• Maintained negative working capital of approximately $12.3 million as of December 31, 2025.
• Highly dependent on its subsidiaries, particularly Lucid Diagnostics, for funding operations, and the potential inability of Lucid to make cash payments or termination of the management services agreement could severely impact PAVmed.
• The 2026 Note requires annual cash interest payments of approximately $2.25 million and mandates a minimum cash balance of $5 million, increasing to $8 million by July 1, 2026.
• The company has faced significant challenges raising capital under current market conditions.
• The exercise of Series D warrants is not assured, potentially requiring alternate capital sources.
• The company's common stock previously traded below the Nasdaq $1 minimum bid price requirement, necessitating a reverse stock split.

Risks

• Incurred operating losses since inception and may not be able to achieve profitability.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Significant challenges in raising capital under current market conditions, with no assurance of future funding on commercially reasonable terms.
• No assurance that common stock will continue to trade on the Nasdaq Capital Market or another national securities exchange.
• Future issuance of common and/or preferred stock by Lucid Diagnostics may dilute PAVmed's equity interest and reduce its influence.
• Servicing indebtedness, including the 2026 Note, requires significant cash and is subject to restrictive covenants that could adversely affect liquidity and financial condition.
• The company will need substantial additional funding and may be unable to raise capital when needed, potentially forcing delays, reductions, or abandonment of growth initiatives or product development programs.
• Operates in highly competitive markets and may not be able to effectively compete against other medical device providers with greater resources.
• Finite resources may restrict success in commercializing current and future products, and third-party arrangements may be unsuccessful.
• Difficulty deploying and maintaining effective sales, marketing, and medical affairs capabilities could hinder market awareness and product sales.
• Products may never achieve market acceptance.
• Recommendations, guidelines, and quality metrics issued by various organizations may significantly affect payors' willingness to cover and healthcare providers' willingness to prescribe products.
• Manufacturing and processing capacity, whether internal or third-party, may be insufficient to meet production requirements or consumer demand.
• Inadequate facility space and capabilities could delay EsoGuard processing times if demand grows, and disruptions to facilities could materially harm business operations.
• Investments in products not yet developed may not be realized, leading to no revenue generation.
• Products and services may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Products and services may cause serious adverse side effects or death, delaying or preventing regulatory approval, limiting commercial desirability, or resulting in negative consequences post-marketing.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Inability to protect or enforce intellectual property rights could impair competitive position.
• Subject to intellectual property infringement claims by third parties, which could be costly and divert management's attention.
• Competitors may violate intellectual property rights, leading to litigation expenses and diversion of attention.
• Business may suffer if unable to manage growth effectively.
• Success is totally dependent upon the efforts of key personnel, and unexpected loss could be detrimental.
• Officers and directors may have conflicts of interest due to fiduciary obligations to other companies.
• Business, financial condition, and results of operations could be adversely affected by political and economic conditions in countries of business.
• Failure in information technology or storage systems could significantly disrupt operations and research and development efforts.
• May become the subject of various claims, threats of litigation, or investigations.
• If private or governmental third-party payors do not maintain adequate reimbursement rates, commercialization efforts could be limited or slowed.
• Future products or services may not be approved for sale, and necessary clinical trials are expensive and difficult to enroll.
• Clinical trial results may not support product candidate claims or may result in the discovery of adverse side effects.
• Even with regulatory approval, ongoing regulatory obligations and review may result in significant additional expense and penalties for non-compliance.
• Healthcare reform measures, including those targeting Medicare or Medicaid, could hinder or prevent commercial success.
• Failure to comply with healthcare regulations could lead to substantial penalties.
• Medical products may be subject to product recalls, harming reputation and financial results.
• Medical products causing death, serious injury, or malfunction trigger medical device reporting regulations, potentially leading to corrective actions or enforcement.
• Promoting unapproved or off-label uses or engaging in other noncompliant activities could result in recalls, seizures, fines, and reputational damage.
• Future issuance of common and/or preferred stock (including shares upon exercise of Series D warrants) could reduce stockholders' equity interest and potentially cause a change in control.
• The holder of the company's debt has certain rights with respect to Lucid Diagnostics shares, which may impact shareholder returns upon disposition.
• Management and their affiliates control a substantial interest, potentially influencing stockholder votes.
• A robust public market for common stock may not be sustained, affecting liquidity and market price.
• Stock price may be volatile, leading to substantial losses for purchasers.
• Outstanding warrants and other convertible securities may have an adverse effect on the market price of common stock and investment value.
• No intention to pay cash dividends on common stock at this time.
• No assurance of future distributions of Lucid common stock to shareholders.
• Subject to evolving corporate governance and public disclosure expectations and regulations, increasing compliance costs and risks.
• Incurs significant costs as a public company, requiring substantial management time for compliance initiatives.
• Material weaknesses in internal control over financial reporting in the future could harm the business.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, stock price and trading volume could decline.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts to replace current management.

Future Outlook

PAVmed expects to continue incurring operating losses for the foreseeable future and anticipates retaining earnings to finance business growth rather than paying cash dividends. The company plans to raise additional capital directly or through its subsidiaries to support business growth and long-term operations. It aims to expand EsoGuard's commercialization and pursue strategic partnerships for Veris Cancer Care Platform adoption. A 510(k) submission for the Veris implantable monitor is planned as early as late 2026, resources permitting. PAVmed will also continue to evaluate opportunities to expand its medical device portfolio through internal development and external licensing, with gross margins for services expected to fluctuate based on commercialization efforts. Sales, marketing, and general and administrative expenses are anticipated to decrease compared to historical periods prior to September 30, 2024, due to Lucid's deconsolidation.

Management Comments

• "We believe that Lucid's flagship product, the EsoGuard Esophageal DNA Test, performed on samples collected with the EsoCheck Esophageal Cell Collection Device, constitutes the first and only commercially available diagnostic test capable of serving as a widespread testing tool with the goal of preventing EAC deaths, through early detection of esophageal precancer in at-risk GERD patients."
• "We believe EsoGuard, used with EsoCheck, constitutes that missing element—the first and only commercially available diagnostic test capable of serving as a widespread testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer and cancer in patients with 3 or more risk factors."
• "We believe Veris Healths offerings can help drive costs down and improve outcomes through providing care teams with better, more continuous data."
• "We do not anticipate paying cash dividends in the foreseeable future but expect to retain earnings to finance the growth of our business."
• "We expect to continue to incur operating losses for the foreseeable future."
• "We intend to continuously reassess and fine-tune our intellectual property strategy in order to fortify our position in the United States and internationally."

Industry Context

StockSavvy.ai notes that PAVmed operates in highly competitive medical device, diagnostics, and digital health sectors. The company's focus on early cancer detection (EsoGuard for Esophageal Adenocarcinoma) and personalized cancer care (Veris Health) aligns with growing trends in precision medicine and remote patient monitoring. The successful VA contract for EsoGuard and positive coverage policy from Highmark Blue Cross Blue Shield indicate increasing recognition and adoption of non-invasive diagnostic tools, which is a positive sign for market penetration in a field traditionally dominated by invasive procedures like endoscopy. The licensing of new endoscopic imaging technology also positions PAVmed to potentially enhance existing diagnostic capabilities within the GI space, a key area for early cancer detection.

Comparison to Industry Standards

• EsoGuard demonstrated high sensitivity and specificity, with a negative predictive value of approximately 99% for the detection of Barrett's esophagus (BE) and EAC in screening populations, indicating strong diagnostic performance.
• The U.S. incidence of EAC has increased 500% over the past four decades, while other common cancers have declined or remained flat, highlighting the significant unmet need that EsoGuard aims to address.
• Less than 5% of at-risk patients recommended for screening undergo traditional invasive upper gastrointestinal endoscopy (EGD), positioning EsoGuard as a potentially disruptive, patient-friendly alternative to current standard of care.
• EsoCheck is compared to devices like EndoSign/Cytosponge, with EsoCheck noted for being protected from sample contamination during retrieval, suggesting a potential advantage in sample quality.
• Veris Health's total addressable U.S. market opportunity exceeds $2 billion, based on approximately 2 million new cancer diagnoses in 2024, indicating a substantial market for digital cancer care platforms.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not aware of any pending legal or other proceedings that are reasonably likely to have a material impact on the Company.
• Legal proceedings are subject to inherent uncertainties, and an unfavorable outcome could include monetary damages and excessive verdicts, potentially resulting in a material adverse impact on the company's business, financial position, results of operations, and/or cash flows.

Related Party Transactions

• Lucid Diagnostics is considered a related party, and PAVmed records management fee income (MSA Fee) from Lucid. The monthly fee was $1,050,000, which was increased to $2,227,246 for December 2025 to account for allocable employee bonuses.
• Certain officers and directors have fiduciary obligations to other companies engaged in medical device business activities, which may create conflicts of interest in presenting business opportunities.

Stakeholder Impact

• Shareholders face potential dilution from past and future equity raises (Series D offering, warrants, ATM facilities), stock price volatility, no anticipated cash dividends, and uncertainty regarding future Lucid stock distributions.
• Employees are impacted by stock options and restricted stock awards under incentive plans, potential for new hires (e.g., Chief Business Officer for Medical Devices), and the implications of the 'going concern' doubt on job security.
• Customers (healthcare providers and patients) benefit from expanded access to EsoGuard through the VA contract and Highmark coverage, and potential for improved cancer care through the Veris Health platform, supported by ongoing clinical utility studies.
• Creditors, particularly the holder of the 2026 Note, are subject to significant cash interest payments and minimum cash balance requirements, with restrictive covenants and potential for acceleration upon default, impacting the company's financial flexibility.

Next Steps

• Continue research and development for existing and new products, including PortIO and the Duke University endoscopic imaging technology.
• Pursue clinical trials for product candidates to gather further evidence of safety and efficacy.
• Commercialize new products and services, focusing on market acceptance and penetration.
• Establish and expand sales, marketing, and distribution capabilities for products like EsoGuard and the Veris Cancer Care Platform.
• Protect intellectual property rights and defend against potential infringement claims.
• Evaluate opportunities to acquire or invest in additional businesses, products, and technologies.
• Lucid Diagnostics will monitor MolDx's review of the clinical evidence package for EsoGuard Medicare coverage.
• Veris Health will pursue similar strategic partnerships with other leading institutions to expand adoption of its Cancer Care Platform.
• Veris Health plans to make a 510(k) submission for its implantable physiological monitor as early as late 2026, contingent on resource availability.
• PAVmed's compensation committee approved the reinstatement of the PAVmed Employee Stock Purchase Plan (ESPP), effective April 1, 2026.
• The Series D Preferred Stock Warrants will become callable by the Company upon MolDx's publication of a draft local coverage determination for EsoGuard Medicare coverage.

Key Dates

Recommendation

PAVmed Inc. presents a complex investment profile. While the company has demonstrated strategic progress with key product milestones like the VA contract for EsoGuard, positive reimbursement policies, and the expansion of Veris Health, these operational achievements are overshadowed by persistent financial challenges, including recurring operating losses and an explicit 'going concern' warning from auditors. The recent capital raise provides a temporary liquidity injection but also introduces further dilution and significant debt obligations. Investors should monitor the company's ability to translate its product advancements into sustainable revenue and profitability, as well as its capacity to secure additional non-dilutive funding. The current situation suggests a high-risk, high-reward scenario, warranting a cautious 'Hold' stance until clearer financial stability and a path to profitability are established.

Keywords

Medical Device, Diagnostics, Digital Health, Cancer Prevention, Esophageal Cancer, EsoGuard, EsoCheck, Veris Health, Cancer Care Platform, Intraosseous Vascular Access, PortIO, Endoscopic Imaging, Nasdaq Compliance, Reverse Stock Split, Capital Raise, Convertible Preferred Stock, Warrants, SEC Filing, 10-K, Financial Reporting, Corporate Governance, Risk Factors, Healthcare Regulation, Reimbursement, Clinical Trials, Intellectual Property